Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
March 20, 2024 09:00 ET | Beyond Air™
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
February 12, 2024 16:05 ET | Beyond Air™
Commercial demand for LungFit® PH increasing; manufacturing of upgraded devices is ramping up to meet growing demand PMA supplement for the expansion of LungFit PH label to include cardiac surgery...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Schedules Third Fiscal Quarter 2024 Financial Results Conference Call and Webcast
January 18, 2024 08:00 ET | Beyond Air™
GARDEN CITY, N.Y., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors
December 27, 2023 07:30 ET | Beyond Air™
No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM) Phase 1 study continues to recruit eligible...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023 16:05 ET | Beyond Air™
GARDEN CITY, N.Y., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
November 13, 2023 16:05 ET | Beyond Air™
Provides fiscal year 2025 revenue guidance of $12 - $16 million US pilot trial of LungFit® PRO to treat viral community acquired pneumonia (VCAP) underway with data expected mid-calendar 2024 Beyond...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
November 03, 2023 12:00 ET | Beyond Air™
First-in-human Phase 1 study demonstrates early clinical proof of concept Positive clinical biomarker data demonstrate evidence of immune system activation and the translation of the immunogenic...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast
October 19, 2023 16:05 ET | Beyond Air™
GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® To Participate in the Truist Securities BioPharma Symposium
October 17, 2023 16:05 ET | Beyond Air™
GARDEN CITY, N.Y., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Figure 1
Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice
October 17, 2023 07:30 ET | Beyond Air™
UNO therapy results in a more immunogenic tumor microenvironment (TME) as well as a systemic response that overcomes anti-PD-1 resistance First-in-human Phase 1 clinical study is ongoing with...